Dermata Therapeutics, Inc.(DRMA)

Biotechnology · San Diego, CA

$1.13+0.01 (+1.35%)

Delayed quote: Oct 6, 2026, 12:37 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T16:41:53.765Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:41:53.765Z.

Quote observation: 2026-10-06T16:37:39.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,524,911
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 4,412,764
TTM operating income · period ending 2026-06-30: -8,601,013

FMP input reference: 7afec7845e5c1de7d6a7da79415c7f2016586588c7dc262303e5dc1b6d25f1da

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

DRMA EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

DRMA Competitors' EV/EBIT Ratio

DRMA

Dermata Therapeutics, Inc.

Current

Market Cap

$4.52M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLGN

CollPlant Biotechnologies Ltd.

vs DRMA

Market Cap

$4.53M

EV/EBIT Ratio

N/A

TTM Avg

661.60x

3Y Avg

661.60x

5Y Avg

661.60x

CALC

CalciMedica, Inc.

vs DRMA

Market Cap

$4.63M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BGMS

Bio Green Med Solution, Inc.

vs DRMA

Market Cap

$4.64M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PMCB

PharmaCyte Biotech, Inc.

vs DRMA

Market Cap

$4.38M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LEXX

Lexaria Bioscience Corp.

vs DRMA

Market Cap

$4.86M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AIDX

20/20 Biolabs Inc.

vs DRMA

Market Cap

$4.21M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GRI

GRI Bio, Inc.

vs DRMA

Market Cap

$4.15M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PCSA

Processa Pharmaceuticals, Inc.

vs DRMA

Market Cap

$4.11M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

APVO

Aptevo Therapeutics Inc.

vs DRMA

Market Cap

$4.03M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Dermata Therapeutics, Inc. (DRMA)	$4.52M	N/A	N/A	N/A	N/A
CollPlant Biotechnologies Ltd. (CLGN)vs ›	$4.53M	N/A	661.60x	661.60x	661.60x
CalciMedica, Inc. (CALC)vs ›	$4.63M	N/A	N/A	N/A	N/A
Bio Green Med Solution, Inc. (BGMS)vs ›	$4.64M	N/A	N/A	N/A	N/A
PharmaCyte Biotech, Inc. (PMCB)vs ›	$4.38M	N/A	N/A	N/A	N/A
Lexaria Bioscience Corp. (LEXX)vs ›	$4.86M	N/A	N/A	N/A	N/A
20/20 Biolabs Inc. (AIDX)vs ›	$4.21M	N/A	N/A	N/A	N/A
GRI Bio, Inc. (GRI)vs ›	$4.15M	N/A	N/A	N/A	N/A
Processa Pharmaceuticals, Inc. (PCSA)vs ›	$4.11M	N/A	N/A	N/A	N/A
Aptevo Therapeutics Inc. (APVO)vs ›	$4.03M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

DRMA EV/EBIT Ratio Metrics

DRMA Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics